The oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions announced last week the award of a contract by a new client, Astellas Pharma Inc. (TSE: 4503), a Japanese global pharmaceutical Company.
04 Aug 2020
Japanese global pharma Astellas added to the client roster
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Japanese global pharma Astellas added to the client roster
Physiomics Plc (PYC:LON) | 1.3 0 13.0% | Mkt Cap: 1.76m
- Published:
04 Aug 2020 -
Author:
Derren Nathan -
Pages:
8
The oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions announced last week the award of a contract by a new client, Astellas Pharma Inc. (TSE: 4503), a Japanese global pharmaceutical Company.